China Cinda Asset Management Co., Ltd.

SHSC:1359 Stock Report

Market Cap: HK$45.8b

China Cinda Asset Management Valuation

Is 1359 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1359 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1359 (HK$1.2) is trading above our estimate of fair value (HK$0.54)

Significantly Below Fair Value: 1359 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1359?

Key metric: As 1359 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1359. This is calculated by dividing 1359's market cap by their current earnings.
What is 1359's PE Ratio?
PE Ratio18.1x
EarningsCN¥2.35b
Market CapCN¥42.64b

Price to Earnings Ratio vs Peers

How does 1359's PE Ratio compare to its peers?

The above table shows the PE ratio for 1359 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.6x
2799 China CITIC Financial Asset Management
4x-29.2%HK$49.0b
6881 China Galaxy Securities
9.4x9.8%HK$141.2b
806 Value Partners Group
51.3x61.4%HK$2.8b
1375 Central China Securities
41.7xn/aHK$18.1b
1359 China Cinda Asset Management
18.1x38.1%HK$45.8b

Price-To-Earnings vs Peers: 1359 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the peer average (26.4x).

Price to Earnings Ratio vs Industry

How does 1359's PE Ratio compare vs other companies in the HK Capital Markets Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
2799 China CITIC Financial Asset Management
4x-29.2%US$6.29b
8098 CL Group (Holdings)
3.7xn/aUS$11.03m
No more companies available in this PE range
1359 18.1xIndustry Avg. 23.4xNo. of Companies6PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1359 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the Hong Kong Capital Markets industry average (24.5x).

Price to Earnings Ratio vs Fair Ratio

What is 1359's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1359 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.1x
Fair PE Ratio17.6x

Price-To-Earnings vs Fair Ratio: 1359 is expensive based on its Price-To-Earnings Ratio (18.1x) compared to the estimated Fair Price-To-Earnings Ratio (17.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1359 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$1.20
HK$0.98
-18.4%
34.8%HK$1.32HK$0.64n/a2
Nov ’25HK$1.43
HK$0.98
-31.2%
34.2%HK$1.32HK$0.65n/a2
Oct ’25HK$1.08
HK$0.67
-38.0%
2.9%HK$0.69HK$0.65n/a2
Sep ’25HK$0.63
HK$0.67
+6.4%
2.9%HK$0.69HK$0.65n/a2
Aug ’25HK$0.63
HK$0.81
+28.4%
7.2%HK$0.87HK$0.75n/a2
Jul ’25HK$0.65
HK$0.81
+24.6%
7.4%HK$0.87HK$0.75n/a2
Jun ’25HK$0.75
HK$0.81
+8.0%
7.4%HK$0.87HK$0.75n/a2
May ’25HK$0.71
HK$0.81
+14.0%
7.4%HK$0.87HK$0.75n/a2
Apr ’25HK$0.65
HK$0.81
+24.6%
7.4%HK$0.87HK$0.75n/a2
Mar ’25HK$0.76
HK$0.93
+22.4%
8.7%HK$1.01HK$0.85n/a2
Feb ’25HK$0.73
HK$0.97
+33.3%
9.3%HK$1.06HK$0.85n/a3
Jan ’25HK$0.78
HK$0.97
+24.1%
9.0%HK$1.06HK$0.85n/a3
Dec ’24HK$0.77
HK$0.97
+25.7%
9.0%HK$1.06HK$0.85n/a3
Nov ’24HK$0.77
HK$1.10
+42.2%
21.5%HK$1.48HK$0.85HK$1.434
Oct ’24HK$0.79
HK$1.08
+36.6%
19.8%HK$1.48HK$0.85HK$1.085
Sep ’24HK$0.77
HK$1.12
+45.3%
17.0%HK$1.50HK$1.00HK$0.635
Aug ’24HK$0.83
HK$1.17
+40.8%
16.6%HK$1.51HK$1.00HK$0.635
Jul ’24HK$0.78
HK$1.17
+49.8%
16.6%HK$1.51HK$1.00HK$0.655
Jun ’24HK$0.87
HK$1.18
+35.4%
16.4%HK$1.54HK$1.02HK$0.755
May ’24HK$0.93
HK$1.28
+37.5%
15.9%HK$1.58HK$1.05HK$0.715
Apr ’24HK$0.99
HK$1.32
+33.7%
12.9%HK$1.58HK$1.08HK$0.655
Mar ’24HK$1.07
HK$1.41
+31.4%
9.1%HK$1.60HK$1.28HK$0.764
Feb ’24HK$1.15
HK$1.41
+22.3%
9.1%HK$1.60HK$1.28HK$0.734
Jan ’24HK$1.08
HK$1.36
+26.4%
9.0%HK$1.53HK$1.22HK$0.784
Dec ’23HK$1.00
HK$1.36
+36.5%
9.0%HK$1.53HK$1.22HK$0.774
Nov ’23HK$0.76
HK$1.36
+79.6%
9.0%HK$1.53HK$1.22HK$0.774

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

CSC Financial

HK$197.0b

Provides investment banking services in Mainland China and internationally.

6066

HK$9.92

7D

-2.7%

1Y

33.2%

Genertec Universal Medical Group

HK$8.8b

Offers financing and advisory services in the People’s Republic of China.

2666

HK$4.66

7D

-3.1%

1Y

12.0%

China Renaissance Holdings

HK$4.1b

Provides investment banking and investment management services in Mainland China, Hong Kong, and the United States.

1911

HK$7.27

7D

0%

1Y

-26.2%